Latest news

• NICE gives Lilly’s Verzenios chance to compete with rivals

  CDK4/6 inhibitor class. ... Around 46, 000 women are diagnosed with breast cancer each year in England and Wales, of whom around 8, 000 would be eligible for treatment with a CDK4/6 inhibitor.

• CHMP backs Sanofi’s all-oral sleeping sickness drug

  Among these, Novartis’ CDK4/6 inhibitor Kisqali (ribociclib) was recommended for the treatment of women with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer in combination with fulvestrant

• Novartis claims a rare win at ESMO for PI3K inhibitor class

  16%. Alpelisib was also fairly well tolerated in the 572-patient study, which involved patients whose disease had progressed after earlier treatment with an aromatase inhibitor with or without a ... 6 inhibitor, a newer drug group which includes

• Lilly gets EMA nod for Verzenio in breast cancer

  Eli Lilly has the approval it was looking for in Europe for CDK4/6 inhibitor Verzenio, allowing to challenge rivals from Pfizer and Novartis in breast cancer. ... women. It’s not all been plain sailing for Lilly’s CDK4/6 inhibitor programme however.

• Novartis considers filings for PI3K drug in breast cancer

  Novartis has positive phase III results in hand for its PI3K inhibitor alpelisib in advanced breast cancer patients, which it hopes will be enough to file for regulatory approvals. ... The two regimens were compared in patients whose cancer had